Health Care/Hospital

Xinhua Silk Road: Chinese Lingzhi brand Longevity Valley promotes inheritance of a century-old national treasure to Brunei foreign envoys

BEIJING, May 31, 2023 /PRNewswire/ -- A delegation of the renowned Chinese Lingzhi brand, Zhejiang Longevity Valley Botanical Co., Ltd, recently visited the Embassy ofBrunei Darussalam in China to showcase Chinese traditional culture and wisdom of health philosophy embedded in the brand toBrunei....

2023-06-01 09:47 1984

National Comprehensive Cancer Network Joins Collaboration to Improve Standards in Cancer Care for Vietnam

United States-based NCCN representatives visit Hanoi, Vietnam to work with local experts to improve quality-of-life for patients with cancer throughout the country. PHILADELPHIA and HANOI, Vietnam, June 1, 2023 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®)—a not-for-profit a...

2023-06-01 09:00 2858

Mediso installs 100% cryogen-free 7T MRI at the University of Milano-Bicocca, Italy

BUDAPEST, Hungary, June 1, 2023 /PRNewswire/ -- Mediso Medical Imaging Systems recently installed a state-of-the-art 7T MRI at the University of Milano-Bicocca. The nanoScan® MRI 7T installed is equipped with a state-of-the-art cryogen-free superconducting magnet. Uniquely o...

2023-06-01 09:00 2360

Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders

BRII-297, a first-of-its-kind treatment option for anxiety and depressive disorders, has the potential to enable greater therapeutic adherence and convenience for patients DURHAM, N.C. and BEIJING, June 1, 2023 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or...

2023-06-01 08:00 2441

Amplo Biotechnology Secures Fast Track STTR Funding for AMP-201, a Promising Gene Therapy Targeting Collagen Q Deficiency

SAN DIEGO, May 29, 2023 /PRNewswire/ -- Amplo Biotechnology, a leading US-based biotech company dedicated to developing innovative AAV-based gene therapies for neuromuscular junction disorders announced the award of a Fast Track Phase I/II STTR grant from theNIH-NINDS. This highly competitive gra...

2023-06-01 04:24 2951

Argon Strengthens Biopsy Portfolio with SuperCore Advantage™ Instrument

PLANO, Texas, June 1, 2023 /PRNewswire/ -- Argon Medical Devices, a leading provider of device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology, announced the launch of the SuperCore Advantage™ Semi-Automatic Biopsy Instrument as the newest additio...

2023-06-01 00:57 2299

Advances of Qilu Pharmaceutical's QL1706 in Clinical Research Presented at ASCO Annual Meeting

JINAN, China, June 1, 2023 /PRNewswire/ -- The American Society of Clinical Oncology (ASCO) recently announced the selected abstracts for the prestigious ASCO 2023 Annual Meeting. Four clinical research abstracts on QL1706 (iparomlimab/tuvonralimab), an innovative bifunctional antibody for immun...

2023-06-01 00:55 2295

Vazyme Signs Global Strategic Cooperation Agreement with Azenta

NANJING, China, May 31, 2023 /PRNewswire/ -- Vazyme (688105.SH), China's leading biotechnology company, has officially signed a global strategic cooperation agreement with Azenta Life Sciences ("Azenta", Nasdaq: AZTA), which will promote to establish "one-stop" service process for both companies ...

2023-05-31 22:24 4391

Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 trials at the BIO International Convention

Xanamem® is an oral, brain-penetrant tissue cortisol synthesis inhibitor that has shown promising safety and clinical activity in three placebo-controlled trials and has the potential to treat a variety of neurodegenerative and neuropsychiatric diseases SYDNEY, May 31, 2023 /PRNewswire/ -- Actin...

2023-05-31 20:58 2019

Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction

- Caliway has initiated the subject recruitment in CBL-0204 Phase 2b study. - The study is expected to be completed in Q2 2024, and the topline results are anticipated in Q3 2024. TAIPEI, May 31, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals, a biopharmaceutical company focusing on breakthroug...

2023-05-31 20:15 2854

QBIOTICS TO PRESENT AT SACHS 9TH ANNUAL IMMUNO-ONCOLOGY INNOVATION FORUM AND THE BIO INTERNATIONAL CONVENTION

BRISBANE, Australia, May 31, 2023 /PRNewswire/ -- QBiotics Group Limited ( QBiotics), a clinical stage life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals is pleased to announce thatRichard Godfrey will present to potential partners and investors at t...

2023-05-31 19:00 2526

Asieris' progress in MIBC receives renewed attention with its inclusion in ASCO 2023

SHANGHAI, May 31, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the phase I clinical data of ANTICIPATE ...

2023-05-31 16:00 1641

THINK Surgical's TMINI Miniature Robotic System developed with Sagentia Innovation gains FDA 510(k) clearance

CAMBRIDGE, England, May 31, 2023 /PRNewswire/ -- THINK Surgical, Inc. recently announced that its TMINI™ Miniature Robotic System has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). THINK Su...

2023-05-31 15:00 2147

SNIPR Biome reports positive clinical interim results for groundbreaking, first-in-human, CRISPR-based microbial gene therapy

* SNIPR001 demonstrates proof of principle in reducing E. coli levels in the human gastrointestinal tract * SNIPR001 is a novel CRISPR-Cas therapeutic, selectively targeting antibiotic-resistant E. coli which can cause life-threatening infections in vulnerable hematological cancer patients ...

2023-05-31 14:58 1720

Cambrex Celebrates Grand Opening of New Q1 Scientific Facility in Belgium and Secures First Stability Storage Commercial Agreement

EAST RUTHERFORD, N.J, May 31, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, yesterday celebrated the grand opening of its new Q1 Scientific...

2023-05-31 14:30 1903

【 C.S 】: The first company with Cordyceps sinensis assets as the main body was successfully listed on the US SEC

TAIPEI, May 31, 2023 /PRNewswire/ -- Cordyceps, a Chinese medicinal material, is interestingly being called the "Winter Worm" in Chinese due to its unique physical appearance. The older generations may be familiar with this valuable herb for its effect in restoring energy, promoting longevity, an...

2023-05-31 13:12 2019

Yuhan Corporation and J INTS BIO inked a licensing agreement for a New Drug Candidate targeting HER2 NSCLC

SEOUL, South Korea, May 31, 2023 /PRNewswire/ -- Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO,Anna Jo) for a Tyrosine Kinase Inhibitor (TKI) targeting HER2, 'JIN-A04'. The total contract size is325 million dollar...

2023-05-31 13:02 1463

AffaMed Therapeutics Announces Completion of Patient Enrollment in the Real-World Study in China Evaluating the Safety and Efficacy of DEXTENZA® in Cataract Surgery Patients

SHANGHAI, May 31, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychiat...

2023-05-31 11:39 1998

Waterdrop Inc. Announces Earnings Date Change: First Quarter 2023 Earnings Release Scheduled June 2, 2023

BEIJING, May 30, 2023 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH ) ("Waterdrop" or the "Company"), a leading technology platform de...

2023-05-31 11:19 3111

Ascentage Pharma's Novel Drug Olverembatinib Recommended for a Breakthrough Therapy Designation in China for the Treatment of SDH-Deficient GIST, the Second BTD for the Drug

SUZHOU, China and ROCKVILLE, Md., May 30, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announcedtoday that the Center for Drug Evaluation (CDE) of China Na...

2023-05-31 10:20 1724
1 ... 143144145146147148149 ... 807